BRCA1 and prostate carcinoma: The dream team of Stand Up 2 Cancer and the Prostate Cancer Foundation (SU2C-PCF) [48] identified AR mutations or amplifications (62.7%), TP53 mutations or deletions (53.3%), PTEN deletions (40.7%), RB1 deletions (8.6%), BRCA1/BRCA2 mutations or deletions (14.6%), and CDK12 mutations (4.7%) in metastatic biopsy samples from 150 patients with mCRPC.